Minnesota Medical Technologies Secures $20.6M for StaySure U.S. Launch
March 9, 2026, 4:54 am
Minnesota Medical Technologies secured $20.6 million in Series A funding. This capital propels the U.S. commercialization of StaySure, its FDA-cleared device for fecal incontinence. The non-invasive solution offers a discreet alternative to traditional products. Investment targets distribution, sales, and market education. This marks a pivotal moment for millions seeking advanced continence care solutions. The company aims for broad market penetration.
Minnesota Medical Technologies (MMT) has significantly advanced its mission. The company closed a $20.6 million Series A equity financing round. This substantial investment positions MMT for a major U.S. market entry. The capital fuels the launch of StaySure, a groundbreaking medical device. This marks a critical step in addressing a pervasive global health challenge.
HM Venture Partners and Southeast Minnesota Capital Partners co-led the financing. Their backing signals strong investor confidence in MMT's vision. The round provides crucial financial stability. MMT plans disciplined growth. The funds will reduce existing debt. This strengthens the company's financial foundation for rapid, strategic expansion.
MMT will build robust commercial infrastructure nationwide. A comprehensive distribution network is key. This supports the expansive rollout of StaySure across the United States. The company will strategically expand its specialized teams. Sales, marketing, and customer care personnel are priorities. This workforce expansion targets deep market penetration. It will drive widespread brand awareness across the entire U.S. healthcare sector.
StaySure represents a significant leap in continence care technology. It is a non-invasive, single-use silicone insert. The device is ingeniously designed to manage fecal incontinence effectively. Its discreet profile makes it a viable choice. It offers a clinically validated alternative to existing solutions. Patients gain independence and peace of mind.
Traditional absorbent products often fail to meet patient needs. These include adult diapers and pads. They can cause skin irritation. They frequently compromise dignity. StaySure provides a superior solution. It is designed for comfort and security. This innovative medical device offers genuine improvement for daily life.
Fecal incontinence, also known as accidental bowel leakage, affects a vast global population. More than two percent of people worldwide experience this debilitating condition. This translates to tens of millions. These individuals often rely on inadequate, temporary solutions. This critical market segment remains largely underserved by restorative treatments. MMT directly addresses this urgent, unmet medical need.
MMT developed StaySure in close collaboration with the Mayo Clinic. This partnership ensured rigorous clinical development. Gastroenterologist Dr. Adil Bharucha contributed invaluable expertise. Comprehensive clinical testing at Mayo Clinic confirmed StaySure's efficacy and safety. The U.S. Food and Drug Administration (FDA) granted 510(k) clearance in July 2025. This regulatory approval validates StaySure’s readiness for market.
MMT established a dedicated medical device manufacturing facility in Minnesota. This facility ensures high-quality production of StaySure devices. Localized manufacturing supports efficient supply chain management. It also reinforces MMT's commitment to U.S. operations and job creation. This robust infrastructure is vital for scaling production to meet national demand.
The funding supports extensive physician and patient education initiatives. Awareness is crucial for successful integration of new medical solutions. MMT will inform healthcare providers about StaySure’s unique benefits and application. Patients will learn about this discreet, effective alternative for managing their condition. Broadening adoption hinges on clear communication and widespread understanding. Expanding distribution channels will facilitate crucial patient access.
MMT's leadership team brings substantial industry experience. Executives possess proven backgrounds from highly successful medical device ventures. Rochester Medical Corporation is a notable example. That company was acquired by CR Bard for $262 million in 2013. This leadership expertise guides MMT’s strategic execution. Their insights are invaluable for navigating the competitive medical technology landscape and achieving market success.
StaySure offers a truly life-changing solution. Millions suffering from chronic fecal incontinence can find profound relief. The device provides dignity, comfort, and significantly improved quality of life. It moves beyond mere containment to effective intervention. This innovation empowers individuals to reclaim normalcy in their daily routines. It transforms personal challenges for patients across the U.S. and potentially worldwide.
MMT anticipates rapid market penetration. The company targets a vast, underserved market for continence care. Its clear regulatory pathway and robust funding accelerate commercial progress. StaySure's impending U.S. launch signifies a new era in continence management. MMT aims to become a leading innovator in this vital healthcare segment. The company is poised for sustained growth, driving further innovation in patient solutions.
Minnesota Medical Technologies (MMT) has significantly advanced its mission. The company closed a $20.6 million Series A equity financing round. This substantial investment positions MMT for a major U.S. market entry. The capital fuels the launch of StaySure, a groundbreaking medical device. This marks a critical step in addressing a pervasive global health challenge.
HM Venture Partners and Southeast Minnesota Capital Partners co-led the financing. Their backing signals strong investor confidence in MMT's vision. The round provides crucial financial stability. MMT plans disciplined growth. The funds will reduce existing debt. This strengthens the company's financial foundation for rapid, strategic expansion.
MMT will build robust commercial infrastructure nationwide. A comprehensive distribution network is key. This supports the expansive rollout of StaySure across the United States. The company will strategically expand its specialized teams. Sales, marketing, and customer care personnel are priorities. This workforce expansion targets deep market penetration. It will drive widespread brand awareness across the entire U.S. healthcare sector.
StaySure represents a significant leap in continence care technology. It is a non-invasive, single-use silicone insert. The device is ingeniously designed to manage fecal incontinence effectively. Its discreet profile makes it a viable choice. It offers a clinically validated alternative to existing solutions. Patients gain independence and peace of mind.
Traditional absorbent products often fail to meet patient needs. These include adult diapers and pads. They can cause skin irritation. They frequently compromise dignity. StaySure provides a superior solution. It is designed for comfort and security. This innovative medical device offers genuine improvement for daily life.
Fecal incontinence, also known as accidental bowel leakage, affects a vast global population. More than two percent of people worldwide experience this debilitating condition. This translates to tens of millions. These individuals often rely on inadequate, temporary solutions. This critical market segment remains largely underserved by restorative treatments. MMT directly addresses this urgent, unmet medical need.
MMT developed StaySure in close collaboration with the Mayo Clinic. This partnership ensured rigorous clinical development. Gastroenterologist Dr. Adil Bharucha contributed invaluable expertise. Comprehensive clinical testing at Mayo Clinic confirmed StaySure's efficacy and safety. The U.S. Food and Drug Administration (FDA) granted 510(k) clearance in July 2025. This regulatory approval validates StaySure’s readiness for market.
MMT established a dedicated medical device manufacturing facility in Minnesota. This facility ensures high-quality production of StaySure devices. Localized manufacturing supports efficient supply chain management. It also reinforces MMT's commitment to U.S. operations and job creation. This robust infrastructure is vital for scaling production to meet national demand.
The funding supports extensive physician and patient education initiatives. Awareness is crucial for successful integration of new medical solutions. MMT will inform healthcare providers about StaySure’s unique benefits and application. Patients will learn about this discreet, effective alternative for managing their condition. Broadening adoption hinges on clear communication and widespread understanding. Expanding distribution channels will facilitate crucial patient access.
MMT's leadership team brings substantial industry experience. Executives possess proven backgrounds from highly successful medical device ventures. Rochester Medical Corporation is a notable example. That company was acquired by CR Bard for $262 million in 2013. This leadership expertise guides MMT’s strategic execution. Their insights are invaluable for navigating the competitive medical technology landscape and achieving market success.
StaySure offers a truly life-changing solution. Millions suffering from chronic fecal incontinence can find profound relief. The device provides dignity, comfort, and significantly improved quality of life. It moves beyond mere containment to effective intervention. This innovation empowers individuals to reclaim normalcy in their daily routines. It transforms personal challenges for patients across the U.S. and potentially worldwide.
MMT anticipates rapid market penetration. The company targets a vast, underserved market for continence care. Its clear regulatory pathway and robust funding accelerate commercial progress. StaySure's impending U.S. launch signifies a new era in continence management. MMT aims to become a leading innovator in this vital healthcare segment. The company is poised for sustained growth, driving further innovation in patient solutions.